We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amryt Pharma Plc | LSE:AMYT | London | Ordinary Share | GB00BKLTQ412 | ORD 6P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 143.00 | 151.00 | 170.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
08/9/2016 11:01 | Down? Do my eyes deceive me? | bigwavedave | |
07/9/2016 18:24 | We need some good news from the company to push the share price above the 24p share price placing price and SOON! An update would be appreciated! | papillon | |
07/9/2016 18:22 | Dividing the current AMYT share price (20.5p) by 8 gives 2.56p. Sorry JP your "The share price as it stands is about 2p in old fastnet money" is just plain wrong! 2.56p is around 25% higher than 2p. Basic arithmetic is obviously not your strong point! To the best of my knowledge the "rip off mates rates" price was set at a 30% discount to the 24p placing price. That works out at around 17p, so the current 20.5p share price is approximately 20% above the "mates rate" price. I'm afraid your grasp of basic arithmetic is dire, JP. Did you skip mathematics at school? It appears to be so. In future I suggest you refrain from showing your complete ignorance of basic arithmetic. You're just showing yourself up. | papillon | |
07/9/2016 14:48 | Early_Bird Posts: 4,631 Premium Chat Member Off Topic Opinion: No Opinion Price: 20.50 InterimsToday 14:15due this month I believe so not long to wait here for the next update at the very least as a footnote attached to them or as a separate release. News on: Prelim P3 trials commencing Imlan marketting update Possible Nasdaq listing application >>>>> I don't know the likelyhood of a Nasdaq listing, but biotechs are given much higher ratings on that exchange compared to AIM so BRING IT ON! | papillon | |
07/9/2016 12:48 | LOL, Divmad. Low volume so far today. Only small trades. | papillon | |
07/9/2016 07:16 | Well at least this mini rise is keeping Jacksonpillock off our backs. | divmad | |
06/9/2016 18:09 | Just in the first report which looks really useful! Very grateful, thanks again. | icebreaker | |
06/9/2016 18:05 | Icebreaker, I googled these sites. | papillon | |
06/9/2016 18:02 | That's useful to know Pap - Thanks. | icebreaker | |
06/9/2016 17:57 | All I know, Icebreaker, is that the patient group size will be small and that Phase III will be fast tracked because it's for an "orphan" drug treatment. | papillon | |
06/9/2016 17:53 | Can anyone tell me whether there is a phase III programme whereby we would be able to determine the patient group size, evaluation/result parameters etc. or is this not in the public domain? I am assuming a programme would have been put together by now. Many thanks in advance IB | icebreaker | |
06/9/2016 17:49 | The AMYT Ichimoku chart is very bullish and has been so since the 12th August.. Amryt Pharma 6-Sep-16 20.250▲ Tue AMYT London 12-Aug-16 19.875 Bull Senkou Span Cross Strong 11-Aug-16 18.500 Bull Kumo Breakout 5-Aug-16 15.625 Bull Chikou Span Cross Weak 3-Aug-16 15.250 Bull Tenkan/Kijun Cross Weak 22-Jul-16 15.500 Bull Kijun Sen Cross Weak | papillon | |
06/9/2016 17:15 | A nice little day, roll on the commencement of P3 | alphabravo321 | |
06/9/2016 15:15 | We have take off! | papillon | |
06/9/2016 14:51 | Someone has just paid full ask (20p) for a small amount. | papillon | |
06/9/2016 14:49 | Rising up on excellent volume. Good sign. I see this breaking above my 21p IH&S neckline very soon. Bring it on. I imagine this rise on above average volume is anticipating good news flow soon. Not many shares in free float. The German charitable foundation, Directors and AXA Framlington & Alan Harris own circa 65% of the shares between them. Three of the Directors have big share stakes (over 3%). I'd be happier if Harry Stratford also had a big share stake as well (any share stake!). Can't see any 24p options issued to him either. | papillon | |
06/9/2016 14:32 | I could do with that right now. More realistically, I think it could have another tick or two in it before the bell. | bigwavedave | |
06/9/2016 13:53 | If the AMYT share price isn't 50p by the end of the year then I will eat my hat (if I had one!). | papillon | |
06/9/2016 13:29 | The true bid is currently 19.1p. The offer (online) is also creeping up. | bigwavedave | |
06/9/2016 13:03 | All 4 x 50k trades this morning were buys even the two earliest ones marked up as sells at 18.88p because I know you could buy at 18.88p because I had a small top up just before the close late last night with money I found down the back of the sofa! | papillon | |
06/9/2016 12:04 | Some biggish buys this morning. I do believe that AMYT is going to be a big winner for shareholders. In the short term I see my very bullish Inverse Head & Shoulders pattern progressing nicely on the chart. I expect good news soon. From the lse bb. Early_Bird Posts: 4,624 Premium Chat Member Off Topic Opinion: No Opinion Price: 19.25 Snippet from broker noteToday 10:18" In May 2016, Pfizer purchased Anacor Pharmaceuticals for $5.2 billion in an all cash deal to get access to their Eczema gel which is in a phase three trial at the moment. Amryt has been tracking this company for some time now as Anacor�s lead product is also a topical skincare gel aimed at the pediatric market and just over 3 years ago their market cap would have been sub $150m when the shares traded at $3.19 a share as opposed to around $100 today. This demonstrates the really exciting potential of Amryt as its pharmaceutical product Episalvan is of interest to many of the multinational pharma companies as it has already been approved by the European Medicines Agency earlier this year and will be commencing sales shortly. Furthermore, as soon as the Amryt Phase III trial of Episalvan for Epidermolysis Bullosa gets under way then Amryt is going to be of even more interest to these multinational pharmaceutical companies. " | papillon | |
06/9/2016 10:06 | ...nicely bounced off 50EMA, Stochastic also on the turn, upwards & onwards ;-) | billyrayvalentine | |
06/9/2016 09:17 | Some lifesigns | alphabravo321 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions